Dermata Therapeutics, Inc. Share Price
NASDAQ: DRMA | Micro CapDermata Therapeutics, Inc. Stock Performance
Open $1.11 | Prev. Close $1.11 | Circuit Range N/A |
Day Range $1.09 - $1.11 | Year Range $1.05 - $6.10 | Volume 690 |
Average Traded $1.11 |
Dermata Therapeutics, Inc. Share Price Today
As of 10 August 2026, Dermata Therapeutics, Inc.'s share price is $1.10. The stock opened at $1.11, compared to its previous close of $1.11. During today's trading session, Dermata Therapeutics, Inc.'s share price traded between $1.09 and $1.11, with an average price of $1.10. Over the past 52 weeks, the stock has recorded a high of $6.10 and a low of $1.05. In terms of performance, Dermata Therapeutics, Inc.'s share price has declined by 8.68% over the last six months and is down 80.16% on a year-on-year basis.
Dermata Therapeutics, Inc. Share Price Chart
Dermata Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.02M | PE Ratio (TTM) -0.14 | Dividend Yield N/A |
EPS (TTM) $-8.16 | Revenue (TTM) N/A | Return On Equity (TTM) -121.45% |
Profit Margin N/A | Debt to Equity 0.26 | Quarterly Earnings Growth YoY 46.68% |
Dermata Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Dermata Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.05 | $1.10 | -7.14% |
Jul 2026 | $1.33 | $1.19 | -7.03% |
Jun 2026 | $1.32 | $1.28 | -1.54% |
May 2026 | $1.36 | $1.30 | -4.41% |
Apr 2026 | $1.23 | $1.36 | +7.09% |
Mar 2026 | $1.19 | $1.27 | +4.96% |
Feb 2026 | $2.18 | $1.21 | -46.22% |
Jan 2026 | $2.21 | $2.25 | -4.86% |
Dec 2025 | $2.91 | $2.37 | -22.46% |
Nov 2025 | $3.33 | $3.05 | -10.56% |
Oct 2025 | $4.94 | $3.41 | -33.01% |
Sep 2025 | $5.27 | $5.09 | -8.62% |
DRMA Share Price FAQs
What is Dermata Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Dermata Therapeutics, Inc. stock?
What is DRMA's market capitalisation today?
What is DRMA's net income for the last quarter?
What is the 5 year returns of DRMA?
What is the high & low stock price of DRMA today?
Can I buy DRMA shares in India?